

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No.	Document Number	Publication Date / Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)			
	AA	US1974/3823135	07-09-1974	Pilgram et al.	
	AB	US1996/5512549	04-30-1996	Chen et al.	
	AC	US1996/5580979	12-03-1996	Bachovchin	
	AD	US1997/5614492	03-25-1997	Habener	
	AE	US2000/6156739	12-5-2000	Griffin et al.	
	AF	US2000/6160063	12-26-2000	Villhauer	
	AG	US2001/8258597-B1	07-10-2001	Bachovchin	
	AH	US2001/0020008-A1	09-06-2001	Demuth et al.	
	AI	US2001/6303661-B1	10-16-2001	Demuth et al.	
	AJ	US2001/6319893-B1	11-20-2001	Demuth et al.	
	AK	US2001/0061646-A1	12-13-2001	Demuth et al.	
	AL	US2002/0049153-A1	04-25-2002	Bridon et al.	
	AM	US2002/0049164-A1	04-25-2002	Demuth et al.	
	AN	US2002/6380398-B2	04-30-2002	Kanstrup et al.	
	AO	US2002/0062427-A1	06-27-2002	Demuth et al.	
	AP	US2002/6449045-B1	09-10-2002	Levine et al.	
	AQ	US2002/0196242-A1	12-26-2002	Demuth et al.	
	AR	US2002/0196380-A1	12-26-2002	Belzer et al.	
	AS	US2002/6500804-B2	12-31-2002	Demuth et al.	
	AT	US2003/0008925-A1	01-09-2003	Demuth et al.	
	AU	US2003/6548481-B1	04-15-2003	Demuth et al.	
	AV	US2003/0092630-A2	05-15-2003	Demuth et al.	
	AW	US2003/0119750-A1	06-26-2003	Demuth et al.	
	AX	US2003/0190199-A1	07-10-2003	von Hoersten et al.	
	AY	US2003/0134802-A1	07-17-2003	Demuth et al.	
	AZ	US2003/0195023-A1	07-17-2003	Demuth et al.	
	BA	US2003/0149961-A1	08-07-2003	Heiser et al.	
	BB	US2003/0163609-A1	08-14-2003	Bachovchin et al.	
	BC	US2003/0162820-A1	08-29-2003	Demuth et al.	
	BD	US2003/0169578-A1	09-04-2003	Arch et al.	
	BE	US2003/6620910-B1	09-16-2003	Celas et al.	
	BF	US2003/0176357-A1	09-18-2003	Pospisilik et al.	
	BG	US2003/0199451-A1	10-23-2003	Mogensen et al.	
	BH	US2003/0199672-A1	10-23-2003	Knudsen et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **10****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

BI	US2003/0236272-A1	12-25-2003	Richard David Carr
BJ	US2004/6703236-B2	03-08-2004	Bachovchin
BK	US2004/0054171-A1	03-18-2004	Jensen et al.
BL	US2004/0056676-A1	03-25-2004	Hoffmann et al.
BM	US2004/0132732-A1	07-08-2004	Han et al.
BN	US2004/0167191-A1	08-26-2004	Demuth et al.
BO	US2004/0171555-A1	09-02-2004	Demuth et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>2</sup> - Kind Code <sup>6</sup> (if known)				
	BP	FR 2 162 106 (English Abstract-1873)	11-30-1972	Amschler et al.		
	BQ	WO 89/10701	11-18-1989	BASF		
	BR	EP 0378255-A2	07-18-1990	Janssen Pharmaceutica		
	BS	GB 2230527-A	10-24-1990	Imperial Chemical Industries Plc		
	BT	WO 81/12001	08-22-1981	Merck & Co., Inc.		
	BU	WO 93/21162	01-29-1993	Nissan Chemical Industries, Ltd.		
	BV	WO 93/08259 (A2)	04-29-1993	New England Medical Center Hospitals, Inc.		
	BW	WO 93/08259 (A3)	04-29-1993	New England Medical Center Hospitals, Inc.		
	BX	EP 0547442-A1	06-23-1993	E.R. Squibb & Sons, Inc.		
	BY	WO 94/03055	02-17-1994	U.S. Government, Sec'y, HHS		
	BZ	EP 0587377-A2	03-16-1994	Eli Lilly and Company		
	CA	WO 95/35031	12-28-1995	La Trobe University		
	CB	WO 96/32394	10-17-1996	Taiho Pharmaceutical Co., Ltd.		
	CC	WO 96/38550	12-05-1996	Dana-Farber Cancer Institute, Inc.		
	CD	WO 97/40832	11-06-1997	Hans-Knoll-Institut Fur Naturstoff		
	CE	JP 9259977	11-18-1997	Terumo Corp.		
	CF	WO 98/00439	01-08-1998	Trustees of Tufts College		
	CG	WO 98/24780	06-11-1998	Amgen Inc.		
	CH	WO 99/16864	04-08-1999	Point Therapeutics, Inc.		
	CI	WO 99/38501	08-05-1999	Trustees of Tufts University		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **10****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

CJ	WO 99/50249	10-07-1999	Du Pont Pharmaceuticals Company
OK	WO 99-61431	12-02-1999	Probiolog
CL	WO 99/67278	12-29-1999	Pro-Biolog
CM	WO 99/67279	12-29-1999	Pro-Biolog
CN	WO 00/07617	02-17-2000	Novo Nordisk
CO	WO 00/09666	02-24-2000	U.S. Government, Secty. HHS
CP	WO 00/15211	03-23-2000	Akasis Pharmaceuticals, Inc.
CQ	WO 00/76966-A1	04-11-2000	Probiolog
CR	WO 00/34241	05-15-2000	Novartis AG
CS	WO 00/47219	08-17-2000	Ontogeny, Inc.
CT	WO 00/53171	09-14-00	Molteni L. E. C. Dei Fratelli Aimi Scola' DI Esercizio S.P.A.
CU	WO 00/57721	10-05-2000	Akasis Pharmaceuticals, Inc.
CV	WO 01/14318-A2	03-01-2001	Probiolog
CW	WO 01/34594-A1	05-17-2001	Gulford Pharmaceuticals, Inc.
CX	WO 01/52825-A2	07-26-2001	Novartis AG
CY	WO 01/56989-A1	08-09-2001	Kirin Beer Kabushiki Kaisha
CZ	WO 01/70729-A1	09-27-2001	Sanofi-Synthelabo
DA	WO 01/97806-A1	12-27-2001	Smithkline Beecham PLC
DB	WO 02/34242-A2	05-02-2002	Probiolog AG
DC	WO 02/34243-A2	05-02-2002	Probiolog AG
DD	WO 02/083109-A1	10-24-2002	Ferring BV
DE	JP 2002/338466	11-27-2002	Tanabe Sanyaku Co Ltd
DF	WO 03/002593-A2	01-09-2003	Probiolog AG
DG	WO 03/002595-A2	01-09-2003	Probiolog AG
DH	WO 03/002596-A2	01-09-2003	Probiolog AG
DI	WO 03/016335-A2	02-27-2003	Probiolog AG
DJ	WO 03/022871-A2	03-20-2003	Probiolog AG
DK	WO 03/026652-A1	04-03-2003	Bristol-Myers Squibb Company
DL	WO 03/030946-A1	04-17-2003	Novartis AG
DM	WO 03/033524-A2	04-24-2003	Probiolog AG
DN	JP 2003/128551	05-08-2003	Sankyo Co Ltd
DO	WO 03/040174-A2	05-15-2003	Probiolog AG
DP	WO 03/045228-A2	06-05-2003	Trustees of Tufts College
DQ	WO 03/045977-A2	06-05-2003	Trustees of Tufts College
DR	WO 03/048061-A2	06-12-2003	Bristol-Myers Squibb Company
DS	WO 03/048158-A1	06-12-2003	Bristol-Myers Squibb Company
DT	WO 03/057200-A2	07-17-2003	Novo Nordisk

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1846
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

	DU	WO 03/063603-A2	08-07-2003	Probiolog AG	
	DV	WO 03/072556-A1	09-04-2003	Probiolog AG	
	DW	WO 03/082898-A2	10-06-2003	Probiolog AG	
	DX	WO 03/092605-A2	11-13-2003	Trustees of Tufts College	
	DY	WO 03/09279-A1	12-04-2003	Novartis AG	
	DZ	WO 03/098818-A1	12-04-2003	Chiron Corporation	
	EA	WO 03/106416-A2	12-24-2003	Smithkline Beecham Corporation	
	EB	WO 2004/017989-A1	03-04-2004	Probiolog AG	
	EC	JP 2004/99600-A	04-02-2004	Sankyo Co. Ltd.	
	ED	WO 2004/031374-A2	04-15-2004	Probiolog AG	
	EE	JP 2004/123738-A	04-22-2004	Takeda Chem Ind Ltd	
	EF	WO 2004/037178-A2	05-06-2004	Bristol-Myers Squibb Company	

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	EG	ARGAUD, DORIANE et al., Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes, European J. Biochem. 213, 1341-1348 (1993).	
	EH	ASHCROFT, STEPHEN J.H. et al., Structure-activity relationships of alloxan-like compounds derived from uric acid, Br. J. Pharmac. (1986), 89 pp. 469-472.	
	EI	BAL, GUNTHER, Dipeptidyl Peptidase IV and Prolyl Oligopeptidase: Design, Synthesis and Evaluation of Substrates and Inhibitors, (2002) Universiteit Antwerpen.	
	EJ	BARAKAT, S.E.S., Synthesis and hypoglycemic activity of some new 3-(4-(((cyclohexylamino) carbonyl) amino) sulfonyl phenyl)-4(3H)-quinazolinones, Az. J. Pharm. Sci., Vol. 25, (2000), pp. 48-57.	
	EK	BARAKAT, S.E.S., Synthesis and Hypoglycemic Activity of Some New 4(3H)-Quinazolinone Analogues, Saudi Pharmaceutical Journal, Vol. 6, No.4 (2000) pp.198-204.	
	EL	BAKER, B.R. et al., Irreversible Enzyme Inhibitors. On the Mode of Pyrimidine Binding of 5-alkyl and 5-Arylpyrimidines to Dihydropyridine Reductase (1,2), Journal of Heterocyclic Chemistry Vol. 4 (1967) pp. 39-48.	
	EM	BELGODERE, ELENA et al., Synthesis of Substituted Pyrimidines, Study of the Structure and of the Tautomeric Equilibria, (1976) Chem. Abstracts, Columbus, OH Vol. 85 No. 9.	
	EN	BEZUGLYI, P.O. et al., Synthesis of arylsulfonyl hydrazide of 3-R-quinazolinone-4-carbonyl-2-acid, Pharmaceutical Journal (1979), pp. 70-71.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

EO	BHADURI, A.P. et al., Urinary Metabolite of 2-Piperazino-3 (H)-4-Quinazolinone (Centipiperalone), A Potent Blood Sugar Lowering Agent, Indian J. Biochem. Biophys., Vol. 12 (1975), pp. 413-414.	
EP	BOURAS, MOHAMMED, et al., Metabolism of enterostatin in rat intestine, brain, membranes and serum: differential involvement of proline-specific peptidases, Peptides, Vol. 16, No. 3, (1995), pp. 399-405.	
EQ	BRUN, JEAN-FREDERIC, et al., Effects of Oral Zinc Gluconate on Glucose Effectiveness and Insulin Sensitivity In Humans, Biological Trace Element Research Vol. 47 (1995), pp. 385-391.	
ER	BUCKLEY, DI, Analysis of the Degradation of Insulintropin [GLP-1 (7-37)] In Human Plasma and Production of Degradation Resistant Analogs.	
ES	CHATTERJEE, A.K. et al., Effect of Centipiperalone In Insulin Deficient Diabetes, Indian Journal of Experimental Biology Vol. 18 (1980), pp. 1005-1008.	
ET	CHATTERJEE, A.K. et al., Effect of Centipiperalone, a New Hypoglycemic Agent on Insulin Biosynthesis & Release from Isolated Pancreatic Islets of Rat, Indian Journal of Experimental Biology Vol. 20 (1981) pp.270-272.	
EU	COPPOLA, GARY M. et al., 1-Aminomethylsecohistidine-4-carboxylates as Novel Dipeptidylpeptidase IV Inhibitors, Bioorganic & Medicinal Chemistry Letters Vol. 10 (2000), pp. 1555-1558.	
EV	DEACON, CAROLYN F. et al., Degradation of Glucagon-Like Peptide 1 <i>In Vitro</i> Yields an N-Terminally Truncated Peptide That is a Major Endogenous Metabolite <i>In Vivo</i> , Journal of Clinical Endocrinology and Metabolism Vol. 80, No. 3 (1995), pp. 952-957.	
EW	DEACON, CAROLYN F. et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH <sub>2</sub> -Terminus In Type II Diabetic Patients and In Healthy Subjects, Diabetes, Vol. 44 (1995), pp. 1125-1131.	
EX	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Influences GLP-1 Metabolism <i>In Vivo</i> , Regulatory Peptides Vol. 64 Issues 1-3 (1995) p.30.	
EY	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition Potentiates the Insulintropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig, Diabetes, Vol. 47 (1998), pp. 764-769.	
EZ	DEACON, CAROLYN F. et al., Dipeptidyl peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective, Biochemical and Biophysical Research Communications 294 (2002), pp. 1-4.	
FA	DEMUTH, HANS-ULRICH et al., Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagons-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective" Biochemical and Biophysical Research Communications 299 (2002) pp. 229-232.	
FB	ENGEL, MICHAEL et al., The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism, Proc. Nat. Acad. Sci. Early Edition (2003), pp. 1-6.	
FC	FANTUS, I. GEORGE, et al., Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects <i>In Vitro</i> end <i>In Vivo</i> , J. Clinical Endocrinology & Metabolism (1986), pp. 898-905.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (end by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

FD	GARRATT, PETER J. et al., A Novel Synthesis of Dihydropyrimidines, J. Chem. Soc., Chem. Commun. (1987), pp.568-569.	
FE	GARRATT, PETER J. et al., One-Carbon Compounds as Synthetic Intermediates. The Synthesis of Dihydropyrimidines and Hydroquinazolines by Sequential Nucleophilic Addition to Diphenyl Cyanocarbonimidate With Concomitant Cyclization, J. Org. Chem. (1988), pp. 1062-1069.	
FF	GAZIT, AVIV et al., Typhostins IV—Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4-Anilidoquinazolines, Bioorganic & Medicinal Chemistry, Vol. 4, No.8 (1996) pp. 1203-1207.	
FG	GUERRIERI, N., et al., Vanadium Inhibition of Serine and Cysteine Proteases, Comparative Biochemistry and Physiology Part A 122 (1997), pp.331-338.	
FH	GUPTA, C.M. et al., Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quinazolines and Trizapino- and Trizodolomquinazolones, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India (1968), pp. 392-395.	
FI	GUPTA, C.M. et al., New Potent Blood Sugar Lowering Compound, Nature, Vol. 223 (1969), p. 524.	
FJ	GUPTA, C.M. et al., A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4-(3H)-Quinazolones, 2-Substituted 4-Hydroxypolyethylene 5,6-pyrimidines & 3-Substituted 4-Oxo-pyrido [1,2-a] pyrimidines, Indian Journal of Chemistry, Vol. 9 (1971), pp. 201-206.	
FK	HERMECOZ, ISTVAN et al., Pyrido[1,2-a]Pyrimidines; New Chemical Entities in Medicinal Chemistry, Medicinal Research Reviews, Vol. 8, No. 2 (1988) pp.203-230.	
FL	HINKE, SIMON A. et al., Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1, Biochemical and Biophysical Research Communications, 291 (2002) pp. 1302-1308.	
FM	HINKE, SIMON A. et al., On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors, Diabetes Care, Vol. 25, No. 8 (2002) pp. 1490-1492.	
FN	HOLZ, GEORGE G. et al., Pancreatic Beta-Cells are Rendered Glucose-Competent by the Insulinotropic Hormone Glucagon-Like Peptide-1(7-37), Nature, Vol. 361 (1993), pp. 362-365.	
FO	KHALID, NORANI M., et al., Purification and Partial Characterization of a Prolyl-Dipeptidyl Aminopeptidase From Lactobacillus helveticus CNRZ 32, Applied and Environmental Microbiology (1999), pp. 381-388.	
FP	KIEFFER, TIMOTHY J. et al., Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by Dipeptidyl Peptidase IV, Endocrinology, Vol. 136, No. 8 (1995) 3595-3598.	
FQ	KIMURA, TOSHIKIYO et al., Oral Administration of Insulin as Poly(Vinyl Alcohol)-Gel Spheres in Diabetic Rats, Biological & Pharmaceutical Bulletin, Vol. 19, No. 6 (1996), 897-900.	
FR	KOREEDA, YUJI et al., Isolation and Characterization of Dipeptidyl Peptidase IV From <i>Prevotella foetidis</i> ATCC 15900, Archives of Oral Biology, 46 (2001), 759-766.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

FS	KUSAR, MIHAEL et al., Diethyl N,N-Dimethylaminomethylmaleonate in the Synthesis of Fused Heterocyclic Systems, <i>Heterocyclic Chem.</i> 33 (1996) pp. 1041-1046.	
FT	LI JINPING, et al., Permylolate and Pertungstate—Potent Stimulators of Insulin Effects in Rat Adipocytes: Mechanism of Action, <i>Biochemistry</i> , 34 (1995) 6218-6225.	
FU	LIN, JIAN, Total Synthesis and Biological Evaluation of Fluorocellin-containing Dipeptidyl Esterases as Inhibitors of Dipeptidyl Peptidase IV (CD26), Dissertation presented to State University of New York at Albany, Department of Chemistry (1999).	
FV	LOESER, ERIC et al., Selective N-Alkylation of Primary Amines with Chloroacetamides Under pH-Controlled Aqueous Conditions, <i>Synthetic Communications</i> , 32(3) (2002) pp. 403-409.	
FW	MANNIUCI, EDUARDO, et al., Effect of Metformin on Glucagon-Like Peptide-1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects, <i>Diabetes Care</i> , Vol. 24, No. 3 (2001) 489-494.	
FX	MENTLEIN, ROLF et al., Dipeptidyl-Peptidase IV Hydrolyses gastric Inhibitory Polypeptide, Glucagon-Like Peptide-(1-36)amide, Peptide Histidine Methionine and is Responsible for Their Degradation in Human Serum, <i>Eur. J. Biochem.</i> Vol. 214, 829-835 (1991).	
FY	MEYEROVITCH, JOSEPH et al., Oral Administration of Vanadate Normalizes Blood Glucose Levels in Streptozotocin-Treated Rats, <i>The Journal of Biological Chemistry</i> , Vol. 262, No. 14 (1987) 6859-6862.	
FZ	MALLOY, J. ARDILL et al., Effect of Metformin Treatment on Gastric Acid Secretion Gastrointestinal Hormone Levels in Normal Subjects, <i>Diabetologia</i> , Vol. 19 (1980) 93-96.	
GA	MUKHERJEE, S.S. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on the tissue respiration, glucose uptake and lactic acid production by rat hemidiaphragm, <i>Biochemical Pharmacology</i> , Vol. 23 (1974) 3086-3097.	
GB	MUKHERJEE, S.S. et al., Studies on the Mechanism of Centipiperone-Induced Hypoglycemia, <i>Acta Diabet. Lat</i> 13, 8 (1976) p.8.	
GC	MUKHERJEE, S.S. et al., Chronic Toxicity Studies of a Hypoglycemic Compound: Centipiperone in Rats & Rhesus Monkeys, <i>Indian Journal of Experimental Biology</i> , Vol. 17 (1979) pp. 1346-1349.	
GD	MUKHERJEE, S.S. et al., Tissue Distribution of [ <sup>3</sup> H]Centipiperone after Oral Administration, <i>Indian J. Biochem. Biophys.</i> , Vol. 17 (1980) pp. 399-401.	
GE	MUKHERJEE, SURATH K. et al., A novel hypoglycemic compound, <i>Biochemical Pharmacology</i> , Vol. 22 (1972) pp. 1529-1531.	
GF	MUKHERJEE, SURATH K. et al., Effect of 2-piperazino-4(3H)-quinazolinone monoacetate on some aspects of carbohydrate metabolism of albino rats, <i>Biochemical Pharmacology</i> , Vol. 22 (1973) pp. 2205-2206.	
GG	MUKHERJEE, SURATH K. et al., Studies on the Metabolic Changes Induced by a Synthetic Insulinogenic Agent, <i>Ind. J. Physiol. &amp; Allied Sci.</i> , Vol. 30, No. 3 (1976) pp. 105-116.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

GH	MUKHERJEE, SURATH K. et al., Influence of Timing Oral Dosing of a Novel Hypoglycemic Agent A-4168 In Relation to Food, <i>Diabetologia</i> Vol. 38 A194 Supplement 1 (1995).
GI	MUKHERJEE, Subal S. et al., Studies on the Mechanism of Centipalalone-Induced Hypoglycemia, <i>Acta Diabet. Lat.</i> 13, 8, (1976) pp. 8-19.
GJ	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Part V - Synthesis & Hypoglycemic Activity of Some New 1-[p-(4-OXO-2-Methyl-Phenyl)-3-(4H)-Quinazolinyl] Phenyl] 3-Aryl-2-Ureas, <i>Indian Drugs</i> , 25 (1) (1987) pp. 19-22.
GK	MURTHY, G. RAMA et al., New Hypoglycemic Agents: Synthesis and Hypoglycemic Activity of Some New 1-[p-(4-OXO-2-Substituted-3-(4H)-Quinazolinyl)-Phenyl] Sulphonyl 3-Aryl-Cyclohexyl-2-Thioureas, <i>Current Science</i> , Vol. 66, No. 24 (1987) pp. 1263-1265.
GL	NAKAMURA, SEIJI, et al., Effect of Chronic Vanadate Administration in Partially Dopamaterized Rats, <i>Diabetes Research and Clinical Practice</i> 27 (1995) pp. 51-59. (Abstract Only)
GM	OHKUBO, I. et al., Dipeptidyl Peptidase IV From Porcine Seminal Plasma: Purification, Characterization, and N-Terminal Amino Acid Sequence, <i>J. Biochem. (Tokyo)</i> (1994) 116(5) pp. 1182-1185.
GN	PANDEYA, S.N. et al., Synthesis of Some New Amidine Derivatives As Potent Hypoglycemic Agents, <i>Pharmacological Research Communications</i> , Vol. 17, No.8 (1985) pp. 699-709.
GO	PAULY, R.P. et al., Inhibition of Dipeptidyl Peptidase IV (DPIV) in Rat Results in Improved Glucose Tolerance, <i>Regulatory Peptides</i> Vol. 64, Issues 1-3 (1996) p. 148.
GP	PEDERSON, RAYMOND A. et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor isoleucine Thiazolide, <i>Diabetes</i> , Vol. 47 (1998) pp. 1253-1258.
GQ	PILLAI, SREKUMAR et al., Effects of ATP, Vanadate, and Molybdate on Cathepsin D-catalyzed Proteolysis, <i>The Journal of Biological Chemistry</i> , Vol. 260, No. 14 (1985) pp. 8394-9.
GR	PODANYI, BENJAMIN et al., Nitrogen Bridgehead Compounds. 62. Conformational Analysis of 6, 7, 8, 9-Tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-ones and Their Methyl Derivatives by NMR Spectroscopy, <i>J. Org. Chem.</i> 51 (1986) 394-399.
GS	POJE, M. et al., Diabetogenic action of alloxan-like derivatives of uric acid, <i>Experientia</i> 36 (1980) pp. 78-9.
GT	POJE, M. et al., Oxidation of Uric Acid. 4. Synthesis, Structure, and Diabetogenic Action of 5-Imino-2,4,6-(1H,3H,5H)-pyrimidinetrione Salts and Their Alloxan-like Covalent Adducts, <i>J. Med. Chem.</i> 26 (1983) 861-4.
GU	POLACEK, I. et al., Hypoglycemic Activity of Amine Derivatives, <i>Arzneim.-Forsch./ Drug Res.</i> 28 (1978), 791-93.
GV	PRIDAL, L. et al., Glucagon-Like Peptide-1(7-37) Has a Larger Volume of Distribution Than Glucagon-Like Peptide1(7-36)amide in Dogs and is Degraded More Quickly In Vitro by Dog Plasma, <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , Vol. 21 (1995), pp. 51-59.

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 10

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

GW	RAM, VISHNU JI et al., Synthesis and Antihyperglycemic Activity of Sulfably Functionalized 3H-quinazolin-4-ones, <i>Bioorganic &amp; Medicinal Chemistry</i> 11 (2003), pp. 2439-2444.	
GX	SAWYER, JAMES H. et al., Pyridyl 1,2-epyrindinium Salts. Part 1. Synthesis from 2-Aminopyridines and Interconversion with 2-(2-Acetylnylamino) pyridines, <i>J.C.S. Perkin I</i> (1972), 1138-1143.	
GY	SAXENA, A.M. et al., Mode of action of three structurally different hypoglycemic agents: A comparative study, <i>Indian Journal of Experimental Biology</i> , Vol. 34 (1996), pp. 351-355.	
GZ	SEDO, ALEKSI et al., Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? <i>Biochimica et Biophysica Acta</i> 1550 (2001), pp. 107-116.	
HA	SEKIYA, T. et al., Pyrimidine derivatives. III (1) Synthesis of hypoglycemic 4-alkoxy-2-piperazine-ethyl of 6-polymethylene-pyrimidines, <i>Eur. J. Med. Chem.</i> (1982), 75-78.	
HB	SENTEN, KRISTEL et al., Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors, <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 12 (2002) pp. 2825-2828.	
HC	SETH, M. et al., Syntheses of 2-Substituted & 2,3-Distributed 4(3H)-Quinazolinones, <i>Indian Journal of Chemistry</i> , Vol. 14B (1975), 536-540.	
HD	SHIMAZAWA, RUMIKO et al., Novel Small Molecule Nonpeptide Aminopeptidase N Inhibitors with A Cyclic Imide Skeleton, <i>J. Enzyme Inhibition</i> , Vol. 14 (1999) pp. 259-275.	
HE	SHISHEVA, ASSIA, et al., Insulinlike Effects of Zinc Ion In Vitro and In Vivo; Preferential Effects on Desensitized Adipocytes and Induction of Normoglycemia in Streptozotocin-Induced Rats, <i>Diabetes</i> , Vol. 41 (1992), pp. 982-988.	
HF	SIRYAK, R. S. et al., Synthesis and Biological Properties of Derivatives of 4-Hetero-mercaptopyrazinoline, Translated from <i>Khimiko-farmatshevskii Zhurnal</i> , Vol. 20, No. 2, pp. 168-171 (1985), pp. 109-105.	
HG	SOKAL, JOSEPH E., Basal Plasma Glucagon Levels of Man, <i>Journal of Clinical Investigation</i> , Vol. 46, No.5 (1987) pp. 778-785.	
HH	SRIVASTAVA, P.P. et al., Efficacy of Centipipalones in Combination With Biguanide & Sulfonylurea, <i>Indian Journal of Experimental Biology</i> , Vol. 21 (1983), pp. 390-392.	
HI	TANAKA, KEIJI et al., Vanadate Inhibits the ATP-Dependent Degradation of Proteins in Reticulocytes Without Affecting Ubiquitin Conjugation, <i>The Journal of Biological Chemistry</i> , Vol. 259, No. 4 (1983), 2803-2809.	
HJ	VILLHAUER, EDWIN B. et al., DPP-IV Inhibition and Therapeutic Potential, <i>Annual Reports in Chemistry</i> 36 (2001), 191-200.	
HK	VILLHAUER, EDWIN B. et al., 1-[(3-Hydroxy-1-adamantylamino)acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, <i>J. Med. Chem.</i> 46 (2003), pp. 2774-2788.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 10

## Complete If Known

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun Feng
Group Art Unit	1646
Examiner Name	Not Yet Assigned
Attorney Docket Number	SYR-DPP-IV-5004-U

HL	WELLS, CAROL L. et al., Role of Anaerobic Flora in the Translocation of Aerobic and Facultatively Anaerobic Intestinal Bacteria, Infection and Immunity, Vol. 55, No. 11 (1987) pp. 2859-94.	
HM	WIEDEMAN, PAUL E. et al., Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes, Current Opinion in Investigational Drugs, Vol. 4, No. 4 (2003), pp. 412-420.	
HN	YASUDA, NOBUYUKI et al., Enhanced Secretion of Glucagon-Like Peptide 1 by Biguanide Compounds, Biochemical and Biophysical Research Communications 298 (2002), pp. 779-784.	
HO	YUEN, V.G. et al., Acute and Chronic Oral Administration of Bis(maltolato)oxovanadium(IV) in Zucker Diabetic Fatty (ZDF) Rats, Diabetes Research and Clinical Practice 43 (1999), pp. 9-19.	
HP	ZANDER, METTE, et al., Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes, Diabetes Care, Vol. 24, No. 4 (2001) pp. 720-725.	
HQ	ZHANG, ANQI et al., Vanadate Stimulation of Insulin Release in Normal Mouse Islets, The Journal of Biological Chemistry, Vol. 266, No. 32 (1991), pp. 21649-56.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **14****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number		Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (If known)				
	AA	US	3,960,949	6/1/1978	Ahr�ns, Hanns et al.	
	AB	US	4,494,978	1/22/1985	Chan, David C. K.;	
	AC	US	4,935,493	6/19/1990	Bachovchin, William W. et al.	
	AD	US	5,366,862	11/22/1994	Venton, Duane L. et al.	
	AE	US	5,387,512	02/07/1995	Balani, Suresh K. et al.	
	AF	US	5,433,955	7/18/1995	Bred�horst, Reinhard et al.	
	AG	US	5,462,928	10/31/1995	Bachovchin, William W. et al.	
	AH	US	5,543,398	8/6/1996	Powers, James C. et al.	
	AI	US	5,601,986	2/11/1997	Takacs, Laszlo	
	AJ	US	5,614,379	3/25/1997	MacKellar, Warren C.	
	AK	US	5,624,894	4/29/1997	Bodor, Nicholas S.	
	AL	US	5,611,278	08/22/1998	Okamura, Hideaki et al.	
	AM	US	5,611,281	09/22/1998	Quaroni, Andrea et al.	
	AN	US	5,614,480	9/29/1998	Venton, Duane L. et al.	
	AO	US	5,685,997	3/23/1999	Lohray, Vidya Bhushan et al.	
	AP	US	5,939,560	8/17/1999	Jenkins, Paul D. et al.	
	AQ	US	5,985,532	10/12/1999	Bachovchin, William W.	
	AR	US	5,985,884	11/16/1999	Lohray, Vidya Bhushan et al.	
	AS	US	6,006,753	12/28/1999	Etendic, Sued	
	AT	US	6,011,155	1/4/2000	Vilhauer, Edwin Bernard	
	AU	US	6,090,786	7/18/2000	Augustyns, Koen Jan Ludovicus et al.	
	AV	US	6,107,317	8/22/2000	Vilhauer, Edwin Bernard	
	AW	US	6,110,949	8/29/2000	Vilhauer, Edwin Bernard	
	AX	US	6,124,305	9/26/2000	Vilhauer, Edwin Bernard	
	AY	US	6,129,911	10/10/2000	Faris, Ronald A.	
	AZ	US	2001/0018210	8/30/2001	Bachovchin, William et al.	
	BA	US	2001/0031780	10/18/2001	Kanstrup, Anders et al.	
	BB	US	2001/0047078	11/29/2001	Chang, Yie-Hwa	
	BC	US	6,172,081	1/9/2001	Damon, Robert	
	BD	US	6,184,020	2/6/2001	Blinkovsky, Alexander et al.	
	BE	US	6,201,132	3/13/2001	Jenkins, Paul D. et al.	
	BF	US	6,214,340	4/10/2001	Takouchi, Tomio et al.	
	BG	US	6,235,493	5/22/2001	Bissell, Eugene R. et al.	
	BH	US	6,251,391	6/28/2001	Wilkinson, Randall Eugene et al.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **2** of **14****Complete if Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

BI	US 6,261,794	7/17/2001	Chang, Yie-Hwa
BJ	US 6,265,551	7/24/2001	Duke-Cohan, Jonathan S. et al.
BK	US 6,308,868	10/30/2001	Monod, Michel
BL	US 6,310,069	10/30/2001	Lohray, Vidya Bhushan et al.
BM	US 6,325,989	12/4/2001	Duke-Cohan, Jonathan S. et al.
BN	US 2002/0006899	1/17/2002	Pospelilik, Andrew J. et al.
BO	US 2002/0019411	2/14/2002	Robt, Jeffrey A. et al.
BP	US 2002/0037829	3/28/2002	Aronson, Peter S. et al.
BQ	US 2002/0041871	4/11/2002	Brudnak, Mark A.
BR	US 2002/0061839	5/23/2002	Scharpe, Simon Lodewijk et al.
BS	US 2002/0071838	6/13/2002	Dernuth, Hans-Ulrich et al.
BT	US 2002/0077340	06/20/2002	Sulsky, Richard et al.
BU	US 2002/0082292	6/27/2002	Sahoo, Soumya P. et al.
BV	US 2002/0103242	6/1/2002	Sahoo, Soumya P. et al.
BW	US 2002/0103384	6/1/2002	Karstrup, Anders et al.
BX	US 2002/0110560	6/15/2002	Dernuth, Hans-Ulrich et al.
BY	US 2002/0115843	08/22/2002	Oi, Steve et al.
BZ	US 2002/0132979	9/19/2002	Chen, Wen-Tien
CA	US 2002/0147130	10/10/2002	Huber, Brigitte T. et al.
CB	US 2002/0147157	10/10/2002	Connor, Gregory S.
CC	US 2002/0155565	10/24/2002	Garin-Chess, Pilar et al.
CD	US 2002/0161000	02/07/2002	Okabe, Yoshiaki et al.
CE	US 2002/0164759	11/7/2002	Travis, James et al.
CF	US 2002/0165164	11/7/2002	Dernuth, Hans-Ulrich et al.
CG	US 2002/0183367	12/5/2002	Sulsky, Richard B. et al.
CH	US 2002/0193390	12/19/2002	Villhauer, Edwin Bernard
CI	US 2002/0198205	12/26/2002	Himmelsbach, Frank et al.
CJ	US 6,335,429	1/1/2002	Cai, Sui Xiong et al.
CK	US 6,337,069	1/8/2002	Grouzmann, Eric et al.
CL	US 6,342,811	1/29/2002	Weber, Eckard et al.
CM	US 6,355,814	3/12/2002	Walther, Barbara P.
CN	US 6,395,767	5/28/2002	Robt, Jeffrey A. et al.
CO	US 6,432,969	8/13/2002	Villhauer, Edwin Bernard
CP	US 6,447,772	9/10/2002	Houston, Devin B.
CQ	US 6,458,924	10/1/2002	Kruidsen, Liselotte Bjarre et al.
CR	US 6,485,955	11/26/2002	Huber, Brigitte T. et al.
CS	US 6,495,544	12/17/2002	Hansen, Jr., Donald W. et al.
CT	US 2003/0008905	1/9/2003	Dernuth, Hans-Ulrich et al.

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-0199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **14****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

CJ	US 2003/0027282	2/6/2003	Huber, Brigitte T. et al.	
CV	US 2003/0040478	2/27/2003	Drucker, Daniel J. et al.	
CW	US 2003/0045464	3/6/2003	Hemmeling, Ronald Norbert et al.	
CX	US 2003/0050562	3/20/2003	Peters, Stetan et al.	
CY	US 2003/0060412	3/27/2003	Prouty, Walter Francis et al.	
CZ	US 2003/0060434	3/27/2003	Nielsen, Loretta et al.	
DA	US 2003/0067935	5/6/2003	Cheng, Peter T. et al.	
DB	US 2003/0067950	5/6/2003	DeNantou, Guillaume et al.	
DC	US 2003/0069935	5/15/2003	Fan, Tao-Hung et al.	
DD	US 2003/0069697	5/15/2003	Cheng, Peter T. et al.	
DE	US 2003/0069646	5/22/2003	Cheng, Peter T. et al.	
DF	US 2003/0069657	5/22/2003	Evans, David Michael et al.	
DG	US 2003/0100563	5/29/2003	Edmondson, Scott D. et al.	
DH	US 2003/0103968	6/5/2003	Amelsberg, Andree et al.	
DI	US 2003/0105077	6/5/2003	Kanstrup, Anders Benditz et al.	
DJ	US 2003/0119736	6/26/2003	Demuth, Hans-Ulrich et al.	
DK	US 2003/0119738	6/26/2003	Niestroj, Andre et al.	
DL	US 2003/0125304	7/3/2003	Demuth, Hans-Ulrich et al.	
DM	US 2003/0130281	7/10/2003	Boehringer, Markus et al.	
DN	US 2003/0130306	7/10/2003	Devasathala, Pratik et al.	
DO	US 2003/0139429	7/24/2003	Cohen, David Saul et al.	
DP	US 2003/0139434	7/24/2003	Balkan, Bork et al.	
DQ	US 2003/0144208	7/31/2003	Knudsen, Lotte Bjerne et al.	
DR	US 2003/0149071	8/7/2003	Gobbi, Luca Claudio et al.	
DS	US 2003/0166562	9/4/2003	Fryburg, David Albert et al.	
DT	US 2003/0166590	9/4/2003	Ebdrup, Soren et al.	
DU	US 2003/0171358	9/11/2003	Jeppesen, Lone et al.	
DV	US 2003/0171411	9/11/2003	Kodra, Janos Tibor et al.	
DW	US 2003/0181497	9/25/2003	Chen, Ping et al.	
DX	US 2003/0186963	10/2/2003	Dorwald, Florencio Zaragoza et al.	
DY	US 2003/0187254	10/2/2003	Perry, David A. et al.	
DZ	US 2003/0191112	10/9/2003	Dorwald, Florencio Zaragoza et al.	
EA	US 2003/0195188	10/16/2003	Boehringer, Markus et al.	
EB	US 2003/0195190	10/16/2003	Peschke, Bernd et al.	
EC	US 2003/0195628	10/23/2003	Kanstrup, Anders B. et al.	
ED	US 2003/0198563	10/23/2003	Robl, Jeffrey A. et al.	
EE	US 2003/0203946	10/30/2003	Behrens, Carsten et al.	
EF	US 2003/0216382	11/20/2003	Boehringer, Markus et al.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 14

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

EG	US 2003/0216450	11/20/2003	Evans, David Michael et al.
EH	US 2003/0220345	11/27/2003	Hamby, James Marino et al.
EF	US 2003/0225102	12/4/2003	Sankaranarayanan, Alangudi
EJ	US 2003/0232761	12/18/2003	Hinkle, Simon A. et al.
EK	US 6,521,644	2/18/2003	Broqua, Pierre
EL	US 6,528,486	3/4/2003	Larsen, Bjørn Dues et al.
EM	US 6,545,170	4/8/2003	Pitzele, Barnett S et al.
EN	US 6,546,529	4/15/2003	Robt, Jeffrey A. et al.
EO	US 6,555,519	4/29/2003	Washburn, William N.
EP	US 6,555,521	4/29/2003	Hermeling, Ronald Norbert et al.
EQ	US 6,559,166	5/6/2003	Gatlin, Marjorie Regan et al.
ER	US 6,573,066	6/3/2003	Chen, Wen-Tien
ES	US 6,573,287	6/3/2003	Sulsky, Richard B. et al.
ET	US 6,586,196	7/1/2003	Brown, Nancy J.
EU	US 6,606,038	8/19/2003	Caplan, Shari L. et al.
EV	US 6,617,340	9/9/2003	Villauer, Edwin Bernard
EW	US 6,620,621	9/16/2003	Robt, Jeffrey A.
EX	US 6,627,636	9/30/2003	Robt, Jeffrey A.
EY	US 6,645,995	11/11/2003	Kanstrup, Anders et al.
EZ	US2004/0002495	1/1/2004	Sher, Philip et al.
FA	US2004/0002609	1/1/2004	Hulin, Bernard
FB	US2004/0006062	1/8/2004	Smallheer, Joanne M. et al.
FC	US2004/0009972	1/15/2004	Ding, Charles Z. et al.
FD	US2004/0009996	1/15/2004	Dhar, T. G. Murali et al.
FE	US2004/0034014	2/19/2004	Kanstrup, Anders Benditz et al.
FF	US2004/0053369	3/16/2004	Abbott, Catherine Anne et al.
FG	US2004/0063935	4/1/2004	Yasuda, Kosuke
FH	US2004/0072874	4/15/2004	Sato, Nagaaki et al.
FI	US2004/0072892	4/15/2004	Fukushima, Hiroshi et al.
FJ	US2004/0077645	4/22/2004	Himmelsbach, Frank et al.
FK	US2004/0082497	4/29/2004	Evans, David Michael et al.
FL	US2004/0082607	6/4/2004	Oi, Satoru et al.
FM	US2004/0087567	5/6/2004	Himmelsbach, Frank et al.
FN	US2004/0092476	5/13/2004	Rothermel, John D. et al.
FO	US2004/0097510	5/20/2004	Himmelsbach, Frank et al.
FP	US2004/0106655	6/3/2004	Kitajima, Hiroshi et al.
FQ	US2004/0106656	6/3/2004	Ashton, Wallace T. et al.
FR	US2004/0106602	6/3/2004	Sankaranarayanan, Alangudi et al.

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **5** of **14****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

FS	US2004/0110817	6/10/2004	Hulin, Bernard
FT	US2004/0116326	6/17/2004	Yoshikawa, Seiji et al.
FU	US2004/0132713	7/8/2004	Hulin, Bernard et al.
FV	US2004/0136146	7/15/2004	Fushimi, Nobuhiko et al.
FW	US2004/0136214	7/15/2004	Himmelsbach, Frank et al.
FX	US2004/0138215	7/15/2004	Eckhardt, Matthias et al.
FY	US2004/0147434	7/29/2004	Ansoerge, Siegfried et al.
FZ	US2004/0152192	8/5/2004	Bachovchin, William et al.
GA	US2004/0152745	8/5/2004	Jackson, Paul et al.
GB	US2004/0166125	8/26/2004	Himmelsbach, Frank et al.
GC	US2004/0167133	8/26/2004	Edmondson, Scott D. et al.
GD	US2004/0167341	8/26/2004	Haffner, Curt Dale et al.
GE	US2004/0171104	9/2/2004	Blinkovskiy, Alexander et al.
GF	US2004/0171848	9/2/2004	Haffner, Curt Dale et al.
GG	US2004/0176406	9/9/2004	Gobbi, Luca Claudio et al.
GH	US2004/0176426	9/9/2004	Edmondson, Scott D. et al.
GI	US2004/0180925	9/16/2004	Matsuono, Kenji et al.
GJ	US2004/0186153	9/23/2004	Yasuda, Nobuyuki et al.
GK	US2004/0186796	10/7/2004	Gretzke, Dirk et al.
GL	US2004/0229691	10/21/2004	Broque, Pierre et al.
GM	US2004/0229620	11/18/2004	Bachovchin, William W. et al.
GN	US2004/0229648	11/18/2004	Demuth, Hans-Ulrich et al.
GO	US2004/0236102	11/25/2004	Brockmiller, Linda et al.
GP	US2004/0242556	12/2/2004	Feng, Jun et al.
GQ	US2004/0242558	12/2/2004	Feng, Jun et al.
GR	US2004/0242636	12/2/2004	Haffner, Curt Dale et al.
GS	US2004/0242696	12/2/2004	Hulin, Bernard et al.
GT	US2004/0254167	12/16/2004	Bitu, Tesfaye et al.
GU	US2004/0254226	12/16/2004	Feng, Jun et al.
GV	US2004/0259643	12/23/2004	Macfar, David J. et al.
GW	US2004/0259670	12/23/2004	Feng, Jun et al.
GX	US2004/0259683	12/23/2004	Sakashita, Hiroshi et al.
GY	US2004/0259902	12/23/2004	Boehlinger, Markus et al.
GZ	US2004/0259903	12/23/2004	Boehlinger, Markus et al.
HA	US2004/0259919	12/23/2004	Magnin, David R. et al.
HB	US 6,673,815	1/6/2004	Devasthale, Pratik et al.
HC	US 6,673,829	1/6/2004	Dorwald, Florencio Zaragoza et al.
HD	US 6,686,337	2/3/2004	Connor, Gregory S.

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

14

**Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

HE	US 6,699,671	3/2/2004	Edmondson, Scott D. et al.	
HF	US 6,706,742	3/16/2004	De Nanteuil, Guillaume et al.	
HG	US 6,710,040	3/23/2004	Hulin, Bernard et al.	
HH	US 6,716,843	4/6/2004	De Nanteuil, Guillaume et al.	
HI	US 6,727,261	4/27/2004	Gobbi, Luca Claudio et al.	
HJ	US 6,727,271	4/27/2004	Cheng, Peter T. et al.	
HK	US 6,800,650	10/5/2004	Boehringer, Markus et al.	
HL	US 6,803,357	10/12/2004	Bachovchin, William A. et al.	
HM	US 6,825,189	11/30/2004	Bachovchin, William W. et al.	
HN	US2005/0014732	1/20/2005	Gulve, Eric Arthur et al.	
HO	US2005/0014946	1/20/2005	Demuth, Hans-Ulrich et al.	
HP	US2005/0020574	1/27/2005	Hauel, Norbert et al.	
HQ	US2005/0026921	2/3/2005	Eckhardt, Matthias et al.	
HR	US2005/0032804	2/10/2005	Cypes, Stephen Howard et al.	
HS	US2005/0038020	2/17/2005	Hamann, Lawrence G. et al.	
HT	US2005/0043292	2/24/2005	Parker, Janice C. et al.	
HU	US2005/0043299	2/24/2005	Evans, David M. et al.	
HV	US2005/0058635	3/17/2005	Demuth, Hans-Ulrich et al.	
HW	US 6,861,440	3/1/2005	Boehringer, Markus et al.	
HX	US 6,867,205	3/15/2005	Boehringer, Markus et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
	Country Code <sup>2</sup> - Number <sup>1</sup> - Kind Code <sup>3</sup> (if known)				
HY	DE 2361551A1	6/19/1975	BASF AG		
HZ	DE 2500024A1	7/9/1976	BASF AG,		
IA	EP 0505893	9/30/1992	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
IB	EP 0547514	6/23/1993	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
IC	EP 0574846	12/22/1993	MERCK PATENT GmbH		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **7** of **14****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

	ID	EP 0657452	6/14/1995	MERCK PATENT GmbH		
	IE	EP 0702013	3/20/1996	MERCK PATENT GmbH		
	IF	GB 1441665A	7/17/1976	COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION		
	IG	WO 91/11457	8/8/1991	BUCKLEY, Douglas, I. Et al.		
	IH	WO 95/15309	6/8/1995	FERRING B.V.		
	II	WO 95/29691	11/6/1995	GEORGIA TECH RESEARCH CORPORATION		
	IJ	WO 96/02667	2/1/1996	AMGEN INC.		
	IK	WO 96/16763	5/7/1996	TANABE SEIYAKU CO., LTD.		
	IL	WO 96/19996	5/14/1996	NOVARTIS AG		
	IM	WO 96/50046	11/12/1996	TRUSTEES OF TUFTS COLLEGE		
	IN	WO 96/51603	11/19/1996	NOVO NORDISK BIOTECH, INC.		
	IO	WO 99/02705	1/21/1999	SOCIETE DES PRODUITS NESTLE S.A.		
	IP	WO 99/17799	4/15/1999	TRUSTEES OF TUFTS COLLEGE ET AL		
	IQ	WO 99/18656	4/22/1999	CYTODIA, INC.		
	IR	WO 99/28474	6/10/1999	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES		
	IS	WO 99/46272	9/16/1999	FONDATECH BENELUX N.V.		
	IT	WO 99/47152	9/23/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH		
	IU	WO 99/62914	12/9/1999	POINT THERAPEUTICS, INC.		
	IV	WO 00/10549	3/2/2000	POINT THERAPEUTICS, INC.		
	IW	WO 00/20416	4/13/2000	GANTE, Helga		
	IX	WO 00/40563	7/13/2000	MERCK PATENT GMBH		
	IY	WO 00/43366	7/27/2000	KIRIN BEER KABUSHIKI KAISHA		
	IZ	WO 00/56296	9/28/2000	FERRING BV		
	JA	WO 00/56297	9/28/2000	FERRING B.V.		
	JB	WO 01/16301	3/8/2001	TUFTS UNIVERSITY		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is etched. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **8** of **14****Complete if Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

JC	WO 01/19866	3/22/2001	THE UNIVERSITY OF SYDNEY		
JD	WO 01/40180	6/7/2001	FERRING BV		
JE	WO 01/55105	8/2/2001	NOVO NORDISK A/S		
JF	WO 01/62266	8/30/2001	NOVO NORDISK A/S		
JG	WO 01/68603	9/20/2001	BRISTOL-MYERS SQUIBB CO.		
JH	WO 01/72290	10/4/2001	PROBODRUG GESELLSCHAFT FÜR ARZNEIMITTELFORSCHUNG MBH		
JI	WO 01/74299	10/11/2001	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK		
JJ	WO 01/79206	10/25/2001	SUMITOMO PHARMACEUTICALS COMPANY, LIMITED		
JK	WO 01/81304	11/1/2001	FERRING BV		
JL	WO 01/81337	11/1/2001	FERRING B.V.		
JM	WO 01/89569	11/29/2001	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH IMTM		
JN	WO 01/94587	12/13/2001	PROZYMEX A/S		
JO	WO 02/04610	1/17/2002	BAYER AKTIENGESellschaft		
JP	WO 02/051836	7/4/2002	KYOWA HAKKO KOGYO CO., LTD		
JQ	WO 02/053170	7/11/2002	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (IMTM)		
JR	WO 02/059301	8/1/2002	K.U. LEUVEN RESEARCH AND DEVELOPMENT		
JS	WO 02/059343	8/1/2002	VANDERBILT UNIVERSITY		
JT	WO 02/062764	8/15/2002	TAKEDA CHEMICAL INDUSTRIES, LTD.		
JU	WO 02/066627	8/29/2002	BAYER AKTIENGESellschaft		
JV	WO 02/068420	9/6/2002	BOEHRINGER INGELHEIM PHARMA KG		
JW	WO 02/076450	10/3/2002	MERCK & CO., INC.		
JX	WO 02/083128	10/24/2002	BRISTOL-MYERS SQUIBB COMPANY		
JY	WO 02/08931	1/31/2002	TEN SQUARE		
JZ	WO 02/092127	11/21/2002	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
KA	WO 02/096357	12/5/2002	BRISTOL-MYERS SQUIBB COMPANY		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **9** of **14****Complete if Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

	KB	WO 02/14271	2/21/2002	WELFIDE CORPORATION		
	KC	WO 02/20804	3/14/2002	PROZYMEX A/S		
	KD	WO 02/26703	4/4/2002	PROLIFIX LIMITED		
	KE	WO 02/28742	4/11/2002	JOHANSSON, Thomas		
	KF	WO 02/30890	4/18/2002	TANABE SEIYAKU CO., LTD.		
	KG	WO 02/30891	4/18/2002	TANABE SEIYAKU CO., LTD.		
	KH	WO 02/31134	4/18/2002	FERRING BV		
	KI	WO 02/34900	5/2/2002	THE UNIVERSITY OF SYDNEY		
	KJ	WO 02/38541	5/16/2002	TAISHO PHARMACEUTICAL CO., LTD.		
	KK	WO 02/38742	5/16/2002	THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.		
	KL	WO 03/000180	1/3/2003	MERCK & CO., INC.		
	KM	WO 03/000250	1/3/2003	FERRING BV		
	KN	WO 03/002530	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KO	WO 03/002531	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KP	WO 03/002553	1/9/2003	SMITHKLINE BEECHAM CORPORATION		
	KQ	WO 03/004498	1/16/2003	NOVO NORDISK A/S		
	KR	WO 03/004498	1/16/2003	MERCK & CO., INC.		
	KS	WO 03/010197	2/6/2003	GENSET S.A.		
	KT	WO 03/010314	2/6/2003	GENSET S.A.		
	KU	WO 03/011807	2/13/2003	NOVO NORDISK A/S		
	KV	WO 03/011814	2/13/2003	NOVO NORDISK A/S		
	KW	WO 03/011834	2/13/2003	NOVO NORDISK A/S		
	KX	WO 03/011892	2/13/2003	THE U.S. GOVERNMENT as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES		
	KY	WO 03/014318	2/20/2003	GENZYME CORPORATION		
	KZ	WO 03/015775	2/27/2003	PROBIODRUG AG		
	LA	WO 03/017936	3/6/2003	YALE UNIVERSITY		
	LB	WO 03/024942	3/27/2003	mitsubishi PHARMA CORPORATION		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **10** of **14****Complete if Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

	LC	WO 03/024965	3/27/2003	NOVO NORDISK A/S		
	LD	WO 03/035067	5/1/2003	FERRING B.V.		
	LE	WO 03/037327	5/8/2003	F. HOFFMANN-LA-ROCHE AG		
	LF	WO 03/038123	5/8/2003	NOVARTIS AG		
	LG	WO 03/040114	5/15/2003	BRISTOL-MYERS SQUIBB COMPANY		
	LH	WO 03/051848	6/26/2003	FERRING BV		
	LI	WO 03/053330	3/7/2003	ASTRAZENECA AB		
	LJ	WO 03/055881	7/10/2003	F. HOFFMANN-LA ROCHE AG		
	LK	WO 03/057144	7/17/2003	GUILFORD PHARMACEUTICALS		
	LL	WO 03/057666	7/17/2003	GUILFORD PHARMACEUTICALS		
	LM	WO 03/065983	8/14/2003	MERCK & CO., INC.		
	LN	WO 03/068748	8/21/2003	F. HOFFMANN-LA ROCHE AG		
	LO	WO 03/068757	8/21/2003	F. HOFFMANN-LA ROCHE AG		
	LP	WO 03/072197	9/4/2003	PFIZER PRODUCTS INC.		
	LQ	WO 03/074500	9/12/2003	SANOFI-SYNTHELABO		
	LR	WO 03/076393	9/18/2003	NOVARTIS AG		
	LS	WO 03/077935	9/25/2003	IMTM INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH, NOVARTIS AG		
	LT	WO 03/080070	10/2/2003			
	LU	WO 03/080633	10/2/2003	NIPPON KAYAKU KABUSHIKI KAISHA		
	LV	WO 03/082817	10/9/2003	MERCK & CO., INC.		
	LW	WO 03/082859	10/9/2003	NOVARTIS AG		
	LX	WO 03/084940	10/16/2003	SANKARANARAYANAN, Alangudi		
	LY	WO 03/101449	12/11/2003	PFIZER PRODUCTS INC.		
	LZ	WO 03/101958	12/11/2003	PFIZER PRODUCTS INC.		
	MA	WO 03/104207	12/18/2003	MERCK & CO., INC.		
	MB	WO 03/104208	12/18/2003	MERCK & CO., INC.		
	MC	WO 03/104229	12/18/2003	EISAI CO., LTD.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The citation is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **12** of **14****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

ND	WO 04/048352	6/10/2004	FUJISAWA PHARMACEUTICAL CO., LTD.	
NE	WO 04/050022	6/17/2004	MERCK & CO., INC.	
NF	WO 04/050656	6/17/2004	EISAI CO., LTD.	
NG	WO 04/050658	6/17/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG	
NH	WO 04/052850	6/24/2004	BRISTOL-MYERS SQUIBB COMPANY	
NI	WO 04/058266	7/15/2004	MERCK & CO., INC.	
NJ	WO 04/064778	8/5/2004	MERCK & CO. INC.	
NK	WO 04/067509	8/12/2004	SANWA KAGAKU KENKYUSHO CO., LTD.	
NL	WO 04/068162	8/19/2004	MERCK & CO., INC.	
NM	WO 04/071454	8/26/2004	GUILFORD PHARMACEUTICALS INC.	
NN	WO 04/075815	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH	
NO	WO 04/075891	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH	
NP	WO 04/076401	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH	
NQ	WO 04/076433	9/10/2004	AIC	
NR	WO 04/076434	9/10/2004	AIC	
NS	WO 04/078777	9/16/2004	BIOREXIS PHARMACEUTICAL CORPORATION	
NT	WO 04/080958	9/23/2004	MERCK & CO. INC.	
NU	WO 04/083212	9/30/2004	MERCK & CO., INC.	
NV	WO 04/085661	10/7/2004	MERCK & CO., INC.	
NW	WO 04/087053	10/14/2004	SYRRX, INC.	
NX	WO 04/087950	10/14/2004	MERCK & CO. INC.	
NY	WO 04/087980			
NZ	WO 04/089362	10/14/2004	BAYER PHARMACEUTICALS CORPORATION	
OA	WO 04/098906	10/21/2004	NOVO NORDISK A/S	
OB	WO 04/098925	11/11/2004	SUMITOMO PHARMACEUTICALS CO. LTD.	
OC	WO 04/099134	11/18/2004	PROBIDRUG AG	
OD	WO 04/099185	11/18/2004	PROSIDION LTD.	
OE	WO 04/101514	11/18/2004	FUJISAWA PHARMACEUTICAL CO. LTD.	
OF	WO 04/103276	11/25/2004	TAISHO PHARMACEUTICAL CO., LTD.	
OG	WO 04/103993	12/2/2004	MERCK & CO., INC.	
		12/2/2004	SYRRX, INC.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **13** of **14****Complete if Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

	OH	WO 04/110436	12/23/2004	MERCK & CO., INC.		
	OI	WO 04/111041	12/23/2004	FUJISAWA PHARMACEUTICAL CO., LTD.		
	OJ	WO 04/111051	12/23/2004	BOEHRINGER INGELHEIM INTERNATIONAL GMBH		
	OK	WO 04/112701	12/29/2004	MERCK & CO., INC.		
	OL	WO 05/000846	1/6/2005	F.HOFFMANN-LA ROCHE AG		
	OM	WO 05/003135	1/13/2005	MERCK & CO., INC.		
	ON	WO 05/011581	2/10/2005	MERCK & CO., INC.		
	OO	WO 05/012249	2/10/2005	BRISTOL-MYERS SQUIBB COMPANY		
	OP	WO 05/019168	3/3/2005	PFIZER PRODUCTS INC.		
	OQ	WO 2005/016911	2/24/2005	Symx, Inc.		

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	OR	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335064. Database Accession no. 1447881 & J. HETEROCYCL. CHEM., Vol. 305, 1972, pages 724-730.
	OS	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335065. Database Accession no. 1447134 & J. ORG. CHEM., Vol. 43, 1978, pages 4069-4074.
	OT	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335066. Database Accession no. 386882 & J. CHEM. SOC., 1952, pages 4985-4990.
	OU	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335067. Database Accession no. 389575 & CHEM. BER., Vol. 88, 1968, pages 106-109.
	OV	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335068. Database Accession no. 472441 & YAKUGAKU ZASSHI, Vol. 88, 1968, pages 106-109.
	OW	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335069. Database Accession no. 1447840 & CHEM. BER., Vol. 101, No. 8, 1968, pages 2679-2689.
	OX	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335070. Database Accession no. 1448609 & CHEM. BER., Vol. 101, No. 8, 1968, pages 2679-2689.
	OY	Database Crossfire Bellstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335071. Database Accession no. 4991064, J. CHEM. SOC. PERKIN TRANS. 1, 1990, pages 1370-1380.

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **14** of **14****Complete If Known**

Application Number	10/809,635
Filing Date	March 24, 2004
First Named Inventor	Jun FENG
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	SYR-DPP-IV-5004-U

	OZ	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335072. Database Accession no. 990008, J.PRAKT.CHEM., Vol. 315, 1973, pages 1168-1169.	
	PA	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335073. Database Accession no. 6219070, J.PRAKT.CHEM., Vol. 330, No. 2, 1988, pages 323-324.	
	PB	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335074. Database Accession no. 392446, J.HETEROCYCLCHEM., Vol. 8, 1971, pages 367-371.	
	PC	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335075. Database Accession no. 4742608, J.PRAKT.CHEM., Vol. 333, No. 1, 1991, pages 149-151.	
	PD	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335076. Database Accession no. 490809, & ANGEW.CHEM., Vol. 84, 1972, page 1185.	
	PE	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Frankfurt am Main, DE; XP002335063. Database Accession no. 1625341 & J. HETEROCYCLCHEM., Vol. 12, 1975, pages 693-697.	
	PF	GUPTA, A. et al.: "Fluorine containing Biologically Active Agents: Synthesis of some new Pyrimidine Derivatives" J.IND. CHEM.SOC., Vol. 71 1994, pages 635-638, XP00089664 compound 1	
	PG	Kesarwani, A. P. et al.: Solid-phase synthesis of quinoxalin-[3H]-ones with three-point diversity, Tetrahedron Letters, Vol. 43, (2002) pp. 5579-5581.	
	PH	Reuchman, B.S. et al. "2,4-Diamino-5-benzylpyrimidines and Analogues as antibacterial Agents", Journal of Med. Chem., Vol. 23, 1980, pages 384-391, XP002335048 Scheme II	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.